Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
The peptide-based vaccine induces a t cell-dependent response
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Subscribe To Our Newsletter & Stay Updated
